Is BIOVF or RYLD a better dividend investment in 2026?

BIOVF currently yields 5.02% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between BIOVF and RYLD?

BIOVF has a forward dividend yield of 5.02% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 7.12 percentage points.

Home › Compare › BIOVF vs RYLD

BIOVF vs RYLD: Dividend Comparison 2026

BIOVF yields 5.02% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RYLD wins by $16.7K in total portfolio value

INVESTMENT

TIME HORIZON10 years

BIOVF

● Live price

5.02%

Share price

$39.87

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.8K

Annual income

$691.40

Full BIOVF calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — BIOVF vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BIOVF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BIOVF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BIOVF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOVF

Annual income on $10K today (after 15% tax)

$426.38/yr

After 10yr DRIP, annual income (after tax)

$587.69/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, RYLD beats the other by $1,611.56/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOVF + RYLD for your $10,000?

BIOVF: 50%RYLD: 50%

100% RYLD50/50100% BIOVF

Portfolio after 10yr

$36.2K

Annual income

$1,639.37/yr

Blended yield

4.53%

📊

Analyst Conviction Gap

Where Wall Street is split right now

BIOVF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

3.7

Piotroski

6/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOVF buys

RYLD buys

No recent congressional trades found for BIOVF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBIOVFRYLD

Forward yield	5.02%	12.14% ✓
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$27.8K	$44.5K ✓
Annual income after 10y	$691.40	$2,587.35 ✓
Total dividends collected	$6.0K	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: BIOVF vs RYLD ($10,000, DRIP)

Year	BIOVF Portfolio	BIOVF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$11,202	$501.63	$11,914	$1,213.65	$712.00 → RYLD
2	$12,511	$525.15	$14,099	$1,351.30	$1.6K → RYLD
3	$13,935	$548.15	$16,580	$1,494.55	$2.6K → RYLD
4	$15,481	$570.60	$19,384	$1,642.61	$3.9K → RYLD
5	$17,157	$592.44	$22,535	$1,794.70	$5.4K → RYLD
6	$18,972	$613.63	$26,063	$1,950.00	$7.1K → RYLD
7	$20,934	$634.14	$29,995	$2,107.69	$9.1K → RYLD
8	$23,053	$653.95	$34,361	$2,266.99	$11.3K → RYLD
9	$25,340	$673.04	$39,194	$2,427.12	$13.9K → RYLD
10	$27,805	$691.40	$44,525	$2,587.35	$16.7K → RYLD

BIOVF vs RYLD: Complete Analysis 2026

BIOVF — Stock

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Full BIOVF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this BIOVF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOVF vs SCHD BIOVF vs JEPI BIOVF vs O BIOVF vs KO BIOVF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.